Keyword Search
 
2017 | 2016 | 2015
  • Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer
  • May 16, 2017 - GAITHERSBURG, Md., May 16, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, to the position of Chief Medical Officer.  Dr. Tasker joined the company in April 2016 as Senior Vice President, Clinical Research and Development, with responsibility for overseeing Altimmune’s clinical research and development programs. Bill Enright, President and Chief Executive Officer of Altimmun... 
  • Altimmune, Inc. (Nasdaq: ALT) to Ring The Nasdaq Stock Market Opening Bell
  • May 10, 2017 - ADVISORY, May 10, 2017 (GLOBE NEWSWIRE) -- What: Altimmune, Inc. (Nasdaq:ALT), a clinical stage immunotherapeutic biotechnology company, will visit the Nasdaq MarketSite in Times Square.In honor of the occasion, Bill Enright, Chief Executive Officer, will ring the Opening Bell. Where: Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast StudioWhen: Friday, May 12, 2017 – 9:15 a.m. to 9:30 a.m. ET Altimmune Contact: Matthew Duffy Investor Relations 212-915-0685 m... 
  • Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases
  • May 04, 2017 - GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinical-stage and four clinical-stage dr... 
  • PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market
  • April 26, 2017 - ANNAPOLIS, Md. and GAITHERSBURG, Md., April 26, 2017 (GLOBE NEWSWIRE) -- As previously announced, PharmAthene, Inc. (NYSE MKT:PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Today, the companies announced that, pending approval of the merger between the two companies by PharmAthene's stockholders at a special meeting of PharmAthene's sto... 
  • Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™
  • March 28, 2017 - ... 
  • Altimmune to Present at The Bio Ceo & Investor Conference
  • February 06, 2017 - ... 
  • Pharmathene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
  • January 19, 2017 - ... 
  • Altimmune Announces Acceptance of Heptcell Abstract for Presentation at Bsi/Nvvi Congress 2016
  • December 06, 2016 - ... 
  • Altimmune to Present at THR 28th Annual Piper Jaffray Healthcare Conference
  • November 18, 2016 - ... 
  • Altimmune Announces Poster Presentation of Heptcell Program at 2017 Keystone Symposia Conference
  • October 26, 2016 - ... 
  • Altimmune Announces Addition of Christine Brennan to Board Of Directors
  • September 13, 2016 - ... 
  • Altimmune to Present at 18th Annual Rodman & Renshaw Global Investment Conference
  • August 30, 2016 - ... 
  • Altimmune Receives Barda Contract of Up to $120.2 Million to Fund Clinical Development of First-In-Class Anthrax Vaccine Candidate Nasoshield
  • August 01, 2016 - ... 
  • Altimmune to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
  • July 12, 2016 - ... 
  • Altimmune to Participate in Two Upcoming Conferences
  • May 03, 2016 - ... 
  • Altimmune Announces Participation in Vaccine Development Panel at The Annual Regional Biotech Forum
  • April 13, 2016 - ... 
  • Altimmune Expands Clinical Development Team
  • April 05, 2016 - ... 
  • Altimmune to Present at two Upcoming Conferences
  • March 01, 2016 - ... 
  • Altimmune Announces Presentation at BIO CEO & Investor Conference
  • January 26, 2016 - Gaithersburg, Maryland – Jan. 26, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the BIO CEO & Investor Conference to be held February 8 - 9, 2016 in New York, NY.Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Monday, February 8, 2016 at 8:00 a.m. ET.About Altimmune Altimmune is a clinical stage immunotherapeutic company focused on the development of products to stimulate robust and du... 
  • Altimmune Announces Presentation at Biotech Showcase 2016
  • December 21, 2015 - Gaithersburg, Maryland – DEC. 21, 2015 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 – 13, 2016 in San Francisco, CA.Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Tuesday January 12, 2016 at 4:45 p.m. PST. The presentation will be held in the Hearst room of the Parc 55 Hotel.About Altimmune Altimmune is a clinical stage immunotherapeutic company foc... 
  • Altimmune Chief Scientific Officer to Present at Two Premier Vaccine Conferences
  • October 12, 2015 - Gaithersburg, Maryland – Oct. 12, 2015- Altimmune, Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that Chief Scientific Officer M. Scot Roberts, PhD, will present at two premier vaccine conferences in the coming weeks. The first is Bacillus ACT 2015, the international conference on Bacillus anthracis, B. ceres & B. thuringiensis, to be held later this month in New Delhi, India. The second is Vaccines R&D-2015, presented by the United Scien... 
  • Altimmune Ceo to Present at the 2015 Ladenburg Thalmann Healthcare Conference in New York City
  • September 28, 2015 - Gaithersburg, Maryland – Sept 28, 2015- Altimmune Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that CEO Bill Enright will present at the 2015 Ladenburg Thalmann Healthcare Conference to be held tomorrow at the Sofitel Hotel in New York City. Enright’s presentation will take place at 11:30am ET.For information on Ladenburg Thalmann, please visit www.ladenburg.com.About Altimmune Altimmune is a clinical stage biotechnology company developing next... 
  • Vaxin Changes Company Name to Altimmune
  • September 01, 2015 - Move Reflects Company’s Expansion beyond Vaccines to Include ImmunotherapeuticsGaithersburg, Maryland – Sept 1st 2015- Vaxin Inc., a clinical stage immunotherapy and vaccine company, today announced that it has changed its corporate name to Altimmune, Inc. Vaxin was founded in 1997 to pioneer new-generation vaccine technologies and products. Since then, the company has achieved steady success, developing promising vaccine candidates for biodefense and other public health needs, as well as animal... 
  • Vaxin First-in-Man Phase I Clinical Trial Initiated in Chronically Infected Hepatitis B Patients
  • July 27, 2015 - Gaithersburg, Maryland – July 27 2015- Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, today announced that it has enrolled the first patient into a phase I clinical trial of HepTcell™ (FP-02.2), the company’s immunotherapeutic compound to treat people chronically infected with the hepatitis B virus (HBV). The multicenter trial will be conducted at seven sites within the United Kingdom, and aims to recruit 72 patients with chronic HBV infection.The trial is a randomized, dou... 
  • Vaxin Strengthens Intellectual Property Portfolio
  • July 21, 2015 - Gaithersburg, Maryland – July 21 2015- Vaxin Inc. today announced that it has added key patents to its expanding Intellectual Property (IP) portfolio. The clinical stage vaccine and immunotherapeutics company confirmed that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two patents that protect important elements of its Densigen platform technology for immunotherapeutic treatment of Hepatitis B virus infection, and its RespirVec non-invasive adenoviral... 
  • Study Demonstrates Superior Performance of Vaxin’s Advav Vaccine for Protection against Aerosolized Anthrax
  • April 29, 2015 - Results Published in Clinical Vaccine Immunology Compares AdVAV FavorablyAgainst Only Currently Licensed AlternativeGaithersburg, MD – April 29, 2015 –Vaxin Inc., a clinical stage vaccine development company, today announced that a recently published study demonstrated that utilizing a single vaccination with the company’s AdVAV™ intranasal anthrax vaccine performs as well as the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax®), which requires two vaccinations. AdVAV is administered ... 
  • Vaxin Names Elizabeth Adkins Czerepak as Chief Financial Officer
  • April 13, 2015 - Gaithersburg, Md., April 13, 2015 —Today, Vaxin strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer (CFO). Vaxin develops vaccines for important public health and biodefense needs. Ms. Czerepak is a finance expert with over 20 years of executive experience in the pharmaceutical, biotech, and venture capital industries. As Vaxin’s CFO, she will grow the company’s finance organization, oversee M&A activities, and dri... 

    © 2017 Altimmune, Inc.   All rights reserved.   Terms of Use